Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Alexion Pharmaceuticals)"
Count: 280
Selected: 0
NCT03346083Study Evaluating Betrixaban in Pediatric Participants
NCT02329327A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
NCT01994382Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
NCT05109390A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
NCT05047484A Study of Multiple Doses of ALXN2050 in Healthy Adults
NCT05047458A Study of Single-dose ALXN2050 in Healthy Adults
NCT05016206A Study of the Cardiac Effects of Danicopan in Healthy Adults
NCT04940559Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants
NCT04935294Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
NCT04889690Study of Multiple Doses of Danicopan in Healthy Participants
NCT04889677Study of a Single Dose of Danicopan in Healthy Participants
NCT04889391Study of Radiolabeled Danicopan in Healthy Male Participants
NCT03555539Study of Danicopan in Participants With Hepatic Impairment
NCT03472885Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
NCT03384186A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
NCT03181633A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03124368A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
NCT03108274A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants
NCT03053102Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT01849562Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
NCT01700179Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
NCT01180790Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
NCT00675844An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
NCT00401947A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
NCT00380159Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
NCT00350272Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
NCT00312039Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
NCT00040144Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
NCT00034359Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
NCT04709094A Drug Interaction Study of Danicopan
NCT04709081A Drug Interaction Study of ACH-0145228
NCT06312644Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
NCT06291376Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06208488A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants
NCT06183931Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06173596A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults
NCT06160414A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants
NCT06079372Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
NCT06079359Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
NCT06079281Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT06071442Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
NCT06015750Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
NCT05982938Danicopan Early Access Program
NCT05966467Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05886244Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
NCT05876351Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
NCT05780645A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants
NCT05751642Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants
NCT05746559ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
NCT05708573Potential Drug Interaction Between ALXN2040 and Rosuvastatin